Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,775 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,528)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01283516 | A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase | completed | Phase 1 | 304 | Novartis PharmaceuticalsINDUSTRY | 11 | Mar 15, 2019 | clinicaltrials |
| NCT02340208 | A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47 | completed | Phase 1 / Phase 2 | 76 | Helix BioPharma CorporationINDUSTRY | 1 | Mar 14, 2019 | clinicaltrials |
| NCT00025480 | Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer | completed | Phase 1 | 12 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 13, 2019 | clinicaltrials |
| NCT00003002 | HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer | completed | Phase 1 | 60 | University of WashingtonOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT01786187 | The Symptom Experience Study in Persons With Non-Small Cell Lung Cancer(SES) | completed | Phase 1 / Phase 2 | 87 | Michigan State UniversityOTHER | 1 | Feb 25, 2019 | clinicaltrials |
| NCT02040870 | LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib | completed | Phase 1 / Phase 2 | 103 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 20, 2019 | clinicaltrials |
| NCT01999738 | Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors | completed | Phase 1 | 93 | EndocyteINDUSTRY | 1 | Feb 7, 2019 | clinicaltrials |
| NCT03053219 | Preliminary Evaluation of Safety and Efficacy by [14C] AC0010 Trail and Subsequent AC0010 Treatment | completed | Phase 1 | 7 | Hangzhou ACEA Pharmaceutical Research Co., Ltd.INDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT02364362 | A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 18 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 18, 2019 | clinicaltrials |
| NCT02155465 | Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib | completed | Phase 1 / Phase 2 | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 16, 2019 | clinicaltrials |
| NCT03556436 | Clinical Trial to Evaluate the Safety and Effects of Ethnicity and Food on Pharmacokinetics of YH25448 | completed | Phase 1 | 24 | Yuhan CorporationINDUSTRY | 1 | Jan 16, 2019 | clinicaltrials |
| NCT01286987 | Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors | completed | Phase 1 | 113 | PfizerINDUSTRY | 2 | Jan 10, 2019 | clinicaltrials |
| NCT02403271 | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 124 | Pharmacyclics LLC.INDUSTRY | 1 | Jan 3, 2019 | clinicaltrials |
| NCT02860780 | A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer | completed | Phase 1 | 9 | Eli Lilly and CompanyINDUSTRY | 2 | Dec 14, 2018 | clinicaltrials |
| NCT03085849 | SGI-110 Plus Durvalumab/Tremelimumab in SCLC | completed | Phase 1 | 2 | Catherine ShuOTHER | 1 | Dec 10, 2018 | clinicaltrials |
| NCT00390429 | Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors | completed | Phase 1 / Phase 2 | 81 | University of California, DavisOTHER | 1 | Dec 6, 2018 | clinicaltrials |
| NCT00923520 | A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Dec 5, 2018 | clinicaltrials |
| NCT01323062 | Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects | completed | Phase 1 | 26 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Dec 4, 2018 | clinicaltrials |
| NCT02655913 | Safety and Efficacy of Vitamin C Infusion in Combination With Local mEHT to Treat Non Small Cell Lung Cancer(VCONSCLC) | completed | Phase 1 / Phase 2 | 97 | Clifford Hospital, Guangzhou, ChinaOTHER | 1 | Nov 30, 2018 | clinicaltrials |
| NCT02457793 | A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 24 | Genentech, Inc.INDUSTRY | 1 | Nov 20, 2018 | clinicaltrials |
| NCT02960594 | hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse(TRT-001) | completed | Phase 1 | 93 | Inovio PharmaceuticalsINDUSTRY | 1 | Nov 19, 2018 | clinicaltrials |
| NCT00043823 | Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer | completed | Phase 1 / Phase 2 | 41 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT01801111 | A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment | completed | Phase 1 / Phase 2 | 138 | Hoffmann-La RocheINDUSTRY | 16 | Nov 2, 2018 | clinicaltrials |
| NCT00389805 | Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors | completed | Phase 1 / Phase 2 | 27 | University of California, DavisOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00926640 | A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers | completed | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Oct 19, 2018 | clinicaltrials |
| NCT02913443 | A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC) | completed | Phase 1 | 18 | Hoffmann-La RocheINDUSTRY | 5 | Oct 19, 2018 | clinicaltrials |
| NCT00580398 | Smoking Cessation Intervention for Thoracic Patients | completed | Phase 1 / Phase 2 | 49 | Massachusetts General HospitalOTHER | 1 | Oct 12, 2018 | clinicaltrials |
| NCT00575393 | Gold Sodium Thiomalate in Treating Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 1 | 17 | Mayo ClinicOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT02874664 | A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer | completed | Phase 1 | 46 | StemcentrxINDUSTRY | 2 | Sep 24, 2018 | clinicaltrials |
| NCT01871805 | A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 134 | Hoffmann-La RocheINDUSTRY | 2 | Aug 21, 2018 | clinicaltrials |
| NCT00003202 | Gemcitabine Plus Radiation Therapy or Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 40 | Wake Forest University Health SciencesOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT01901653 | Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 82 | StemcentrxINDUSTRY | 1 | Aug 9, 2018 | clinicaltrials |
| NCT01457469 | Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer | completed | Phase 1 | 6 | Wake Forest University Health SciencesOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT02317016 | Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer | completed | Phase 1 | 44 | AstraZenecaINDUSTRY | 4 | Jul 31, 2018 | clinicaltrials |
| NCT02025114 | Selumetinib in Combination With Gefitinib in NSCLC Patients | completed | Phase 1 / Phase 2 | 34 | National Taiwan University HospitalOTHER | 1 | Jul 10, 2018 | clinicaltrials |
| NCT02835833 | Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors | completed | Phase 1 | 21 | University of Alabama at BirminghamOTHER | 1 | Jul 10, 2018 | clinicaltrials |
| NCT00923741 | Effect of Talactoferrin in Adults With Non-Small Cell Lung Cancer | completed | Phase 1 | 10 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01553916 | Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain | completed | Phase 1 / Phase 2 | 19 | Washington University School of MedicineOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01931787 | CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 1 | 15 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT01234038 | Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel(NSCLC) | completed | Phase 1 / Phase 2 | 116 | Ionis Pharmaceuticals, Inc.INDUSTRY | 4 | Jun 27, 2018 | clinicaltrials |
| NCT02611245 | NIR Fluorescence Imaging Technique in Thoracic Surgery With ICG | completed | Phase 1 | 36 | Chinese Academy of SciencesOTHER_GOV | 1 | Jun 8, 2018 | clinicaltrials |
| NCT00445198 | A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies | completed | Phase 1 / Phase 2 | 86 | AbbVie (prior sponsor, Abbott)INDUSTRY | 3 | Jun 6, 2018 | clinicaltrials |
| NCT01139775 | A Study in Non Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 76 | Eli Lilly and CompanyINDUSTRY | 2 | May 18, 2018 | clinicaltrials |
| NCT00287963 | Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer | completed | Phase 1 | 18 | Medical University of South CarolinaOTHER | 1 | May 17, 2018 | clinicaltrials |
| NCT01204099 | Study of PX-866 and Docetaxel in Solid Tumors | completed | Phase 1 / Phase 2 | 223 | Cascadian Therapeutics Inc.INDUSTRY | 2 | May 16, 2018 | clinicaltrials |
| NCT03515252 | Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer | completed | Phase 1 | 20 | Ivy Life Sciences, Co., LtdINDUSTRY | 0 | May 9, 2018 | clinicaltrials |
| NCT00078390 | Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 9 | ShionogiINDUSTRY | 1 | May 2, 2018 | clinicaltrials |
| NCT01588145 | Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients | completed | Phase 1 / Phase 2 | 273 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 1 | Apr 24, 2018 | clinicaltrials |
| NCT01998126 | Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer | completed | Phase 1 | 14 | University of UtahOTHER | 1 | Apr 2, 2018 | clinicaltrials |
| NCT01520389 | Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment | completed | Phase 1 | 112 | Merrimack PharmaceuticalsINDUSTRY | 1 | Mar 21, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Mar 15, 2019source: clinicaltrials